Ventria Bioscience

VENTRIA BIOSCIENCE AND THE CONTROVERSY 2VentriaBioscience and the Controversy over Plant-Made Medicines

Introduction

The aim of this analysis will be to determine what the best course of action for VentriaBioscience will be for handling the current controversy over plant-made medicines. This study will examine the situation by analyzing the problem faced by the company, discussing the triple bottom line implications, and proposing a solution. As a result of this evaluation, the proposed recommendation will provide a strategy for what Ventria should do to respond to this situation for the most beneficial outcome.

Company Overview

Ventria Bioscience, founded in 1993, is a privately held biopharmaceutical company engaged in development and production of innovative products in human nutrition and human the rapeutics. The company has developed its proprietary protein expression technology called ExpressTec. Product offerings include several proteins with significant applications in human and animal health. Ventria has developed two protein products with significant application over human and animal health, they are  Lactoferrin and Lysozyme and the company branded them Lactiva and  Lysomin respectively. Both these compounds can be found naturally in human breast milk, saliva and tears.The company produces these proteins from self-pollinating crops like rice and barley through its innovative ExpressTec technology (InfoGrok Pharma, 2010 &Lawrence, 2011).

Current Situation

The current situation and main problem facing Ventria is how this small biotechnology start-up firm based in California can navigate a difficult regulatory and stakeholder landscape to bring to market a pioneering product with potentially significant public health benefits. This innovative product and technology is based on growing medical proteins useful in the treatment of childhood diarrhea in genetically modified rice. The significant challenge faced is in the company's efforts to obtain...